$8.82 Billion is the total value of Orbimed Advisors's 136 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 30.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $449,920,000 | +8.5% | 3,710,986 | +9.5% | 5.10% | -3.4% |
| BIIB | Buy | BIOGEN INC | $392,877,000 | +8.1% | 1,436,900 | +12.2% | 4.45% | -3.8% |
| CELG | Buy | CELGENE CORP | $389,737,000 | +8.4% | 3,132,177 | +0.8% | 4.42% | -3.6% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $380,795,000 | +6.7% | 15,311,400 | -7.2% | 4.32% | -5.1% |
| MRK | Buy | MERCK & CO INC | $363,125,000 | +33.7% | 5,714,900 | +23.8% | 4.12% | +18.9% |
| LLY | Buy | LILLY ELI & CO | $280,103,000 | +39.0% | 3,330,200 | +21.6% | 3.18% | +23.7% |
| WMGI | Buy | WRIGHT MED GROUP N V | $278,407,000 | +59.7% | 8,946,234 | +18.0% | 3.16% | +42.1% |
| INCY | Sell | INCYTE CORP | $263,811,000 | +26.3% | 1,973,597 | -5.2% | 2.99% | +12.4% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $237,202,000 | +49.1% | 2,169,200 | +0.5% | 2.69% | +32.7% |
| AMGN | Sell | AMGEN INC | $235,982,000 | -30.8% | 1,438,300 | -38.3% | 2.68% | -38.4% |
| A | AGILENT TECHNOLOGIES INC | $191,913,000 | +16.0% | 3,629,900 | 0.0% | 2.18% | +3.2% | |
| PFE | Buy | PFIZER INC | $184,943,000 | +10.2% | 5,406,100 | +4.6% | 2.10% | -2.0% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $173,023,000 | +36.6% | 1,839,300 | +36.1% | 1.96% | +21.6% |
| AET | Buy | AETNA INC NEW | $167,397,000 | +67.5% | 1,312,400 | +62.8% | 1.90% | +49.0% |
| SHPG | Sell | SHIRE PLCsponsored adr | $156,363,000 | -23.7% | 897,451 | -25.4% | 1.77% | -32.2% |
| HCA | Sell | HCA HOLDINGS INC | $155,288,000 | +4.8% | 1,745,000 | -12.8% | 1.76% | -6.8% |
| HUM | Sell | HUMANA INC | $153,018,000 | -10.3% | 742,300 | -11.3% | 1.73% | -20.2% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $146,545,000 | +12.4% | 378,170 | +6.4% | 1.66% | -0.1% |
| ANTM | Sell | ANTHEM INC | $142,657,000 | -2.9% | 862,600 | -15.6% | 1.62% | -13.6% |
| ABBV | Sell | ABBVIE INC | $135,533,000 | -26.0% | 2,080,000 | -28.9% | 1.54% | -34.2% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $126,795,000 | -10.3% | 14,182,900 | -11.8% | 1.44% | -20.3% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $123,537,000 | +11.6% | 7,241,300 | 0.0% | 1.40% | -0.8% | |
| CNC | New | CENTENE CORP DEL | $117,985,000 | – | 1,655,700 | +100.0% | 1.34% | – |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $117,285,000 | -3.6% | 1,037,000 | -7.4% | 1.33% | -14.3% |
| AGN | Sell | ALLERGAN PLC | $114,058,000 | -29.4% | 477,390 | -38.0% | 1.29% | -37.2% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $111,840,000 | +6.0% | 1,274,100 | 0.0% | 1.27% | -5.7% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $111,729,000 | +45.2% | 5,379,349 | 0.0% | 1.27% | +29.2% | |
| JNJ | Buy | JOHNSON & JOHNSON | $110,177,000 | +11.5% | 884,600 | +3.1% | 1.25% | -0.9% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $103,920,000 | +19.1% | 1,911,000 | +28.0% | 1.18% | +5.9% |
| SGYPQ | Buy | SYNERGY PHARMACEUTICALS DEL | $98,575,000 | -11.3% | 21,153,343 | +16.0% | 1.12% | -21.1% |
| THC | Buy | TENET HEALTHCARE CORP | $94,784,000 | +71.8% | 5,352,000 | +44.0% | 1.07% | +52.8% |
| GKOS | Sell | GLAUKOS CORP | $89,349,000 | +19.5% | 1,741,700 | -20.1% | 1.01% | +6.3% |
| INSM | Sell | INSMED INC | $84,239,000 | +20.1% | 4,810,905 | -9.3% | 0.96% | +6.8% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $83,548,000 | +19.6% | 2,245,925 | -1.3% | 0.95% | +6.4% |
| TMO | Sell | THERMO FISHER SCIENTIFIC INC | $82,053,000 | -27.3% | 534,200 | -33.2% | 0.93% | -35.3% |
| BOLD | AUDENTES THERAPEUTICS INC | $81,820,000 | -6.7% | 4,801,638 | 0.0% | 0.93% | -17.1% | |
| VRAY | Buy | VIEWRAY INC | $80,492,000 | +181.7% | 9,458,567 | +3.6% | 0.91% | +150.5% |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $76,085,000 | +38.3% | 2,717,315 | 0.0% | 0.86% | +23.0% | |
| MGLN | Buy | MAGELLAN HEALTH INC | $75,177,000 | +24.6% | 1,088,727 | +35.8% | 0.85% | +10.8% |
| AGNPRA | New | ALLERGAN PLCpfd conv ser a | $74,832,000 | – | 88,200 | +100.0% | 0.85% | – |
| LOXO | LOXO ONCOLOGY INC | $72,714,000 | +31.0% | 1,728,000 | 0.0% | 0.82% | +16.5% | |
| AERI | AERIE PHARMACEUTICALS INC | $67,844,000 | +19.8% | 1,496,000 | 0.0% | 0.77% | +6.5% | |
| MNKKQ | MALLINCKRODT PUB LTD CO | $65,638,000 | -10.5% | 1,472,700 | 0.0% | 0.74% | -20.4% | |
| INSYQ | INSYS THERAPEUTICS INC NEW | $63,811,000 | +14.2% | 6,071,440 | 0.0% | 0.72% | +1.5% | |
| MDT | MEDTRONIC PLC | $61,757,000 | +13.1% | 766,600 | 0.0% | 0.70% | +0.6% | |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $57,555,000 | +29.9% | 475,900 | +20.0% | 0.65% | +15.4% |
| EGRX | EAGLE PHARMACEUTICALS INC | $55,653,000 | +4.5% | 671,000 | 0.0% | 0.63% | -6.9% | |
| ACHN | ACHILLION PHARMACEUTICALS IN | $55,181,000 | +1.9% | 13,107,200 | 0.0% | 0.62% | -9.4% | |
| ILMN | Buy | ILLUMINA INC | $54,929,000 | +135.5% | 321,900 | +76.7% | 0.62% | +109.8% |
| GILD | Sell | GILEAD SCIENCES INC | $54,397,000 | -28.0% | 800,900 | -24.1% | 0.62% | -35.9% |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $53,901,000 | +33.1% | 371,400 | 0.0% | 0.61% | +18.4% | |
| MYL | New | MYLAN N V | $50,687,000 | – | 1,300,000 | +100.0% | 0.58% | – |
| UNH | UNITEDHEALTH GROUP INC | $48,613,000 | +2.5% | 296,400 | 0.0% | 0.55% | -8.8% | |
| NLNK | NEWLINK GENETICS CORP | $48,000,000 | +134.4% | 1,991,700 | 0.0% | 0.54% | +108.4% | |
| IMMUNOMEDICS INCnote 4.750% 2/1 | $42,261,000 | +42.0% | 30,000,000 | 0.0% | 0.48% | +26.4% | ||
| SYK | STRYKER CORP | $41,641,000 | +9.9% | 316,300 | 0.0% | 0.47% | -2.3% | |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $40,190,000 | – | 1,169,000 | +100.0% | 0.46% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $39,964,000 | – | 1,084,500 | +100.0% | 0.45% | – |
| ISRG | Sell | INTUITIVE SURGICAL INC | $38,630,000 | -58.1% | 50,400 | -65.4% | 0.44% | -62.8% |
| COO | Sell | COOPER COS INC | $38,139,000 | -12.8% | 190,800 | -23.7% | 0.43% | -22.4% |
| NTLA | INTELLIA THERAPEUTICS INC | $37,510,000 | +7.5% | 2,662,180 | 0.0% | 0.42% | -4.5% | |
| DERM | Buy | DERMIRA INC | $34,917,000 | +170.5% | 1,023,673 | +140.5% | 0.40% | +141.5% |
| BGNE | BEIGENE LTDsponsored adr | $33,084,000 | +20.6% | 903,700 | 0.0% | 0.38% | +7.1% | |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $32,049,000 | +88.8% | 1,257,300 | -10.0% | 0.36% | +68.1% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $31,207,000 | – | 1,054,300 | +100.0% | 0.35% | – |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $28,156,000 | -36.6% | 2,109,068 | -28.6% | 0.32% | -43.6% |
| SEM | Buy | SELECT MED HLDGS CORP | $27,852,000 | +152.7% | 2,086,300 | +150.8% | 0.32% | +125.7% |
| RDUS | New | RADIUS HEALTH INC | $27,213,000 | – | 704,100 | +100.0% | 0.31% | – |
| OBSV | New | OBSEVA SA | $27,124,000 | – | 2,605,531 | +100.0% | 0.31% | – |
| SELB | SELECTA BIOSCIENCES INC | $26,389,000 | -16.5% | 1,842,797 | 0.0% | 0.30% | -25.8% | |
| BLUE | BLUEBIRD BIO INC | $25,797,000 | +47.3% | 283,800 | 0.0% | 0.29% | +30.9% | |
| LBIO | LION BIOTECHNOLOGIES INC | $25,203,000 | +7.2% | 3,382,900 | 0.0% | 0.29% | -4.7% | |
| GLPG | GALAPAGOS NVspon adr | $24,435,000 | +34.3% | 283,500 | 0.0% | 0.28% | +19.4% | |
| IMGN | IMMUNOGEN INC | $23,590,000 | +89.7% | 6,095,647 | 0.0% | 0.27% | +69.0% | |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $22,935,000 | -4.2% | 1,084,400 | +27.6% | 0.26% | -14.8% |
| OTIC | OTONOMY INC | $22,664,000 | -23.0% | 1,850,094 | 0.0% | 0.26% | -31.5% | |
| EHTH | EHEALTH INC | $21,913,000 | +13.1% | 1,820,000 | 0.0% | 0.25% | +0.4% | |
| NBRV | NABRIVA THERAPEUTICS AGsponsored adr | $20,135,000 | +101.3% | 1,677,940 | 0.0% | 0.23% | +79.5% | |
| XNCR | XENCOR INC | $20,098,000 | -9.1% | 840,237 | 0.0% | 0.23% | -19.1% | |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $19,110,000 | -76.8% | 441,341 | -79.3% | 0.22% | -79.3% |
| PIRS | PIERIS PHARMACEUTICALS INC | $18,875,000 | +85.0% | 7,259,620 | 0.0% | 0.21% | +64.6% | |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $18,064,000 | +48.7% | 512,900 | +48.4% | 0.20% | +32.3% |
| STDY | STEADYMED LTD | $17,819,000 | +123.1% | 3,072,196 | 0.0% | 0.20% | +98.0% | |
| SVA | SINOVAC BIOTECH LTD | $15,285,000 | -2.9% | 2,667,500 | 0.0% | 0.17% | -13.9% | |
| BCR | BARD C R INC | $14,415,000 | +10.6% | 58,000 | 0.0% | 0.16% | -1.8% | |
| EXAS | Sell | EXACT SCIENCES CORP | $14,240,000 | +12.2% | 602,900 | -36.5% | 0.16% | -0.6% |
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $13,240,000 | -40.6% | 412,600 | -32.9% | 0.15% | -47.2% |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $13,193,000 | – | 1,797,400 | +100.0% | 0.15% | – |
| Buy | AEGERION PHARMACEUTICALS INCnote 2.000% 8/1 | $12,317,000 | +106.1% | 15,000,000 | +87.5% | 0.14% | +84.2% | |
| PRQR | PROQR THRAPEUTICS N V | $11,527,000 | +2.0% | 2,305,446 | 0.0% | 0.13% | -9.0% | |
| NTRA | NATERA INC | $11,320,000 | -24.3% | 1,276,190 | 0.0% | 0.13% | -32.6% | |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $10,948,000 | +85.0% | 1,469,524 | +8.0% | 0.12% | +65.3% |
| BMY | New | BRISTOL MYERS SQUIBB COput | $10,876,000 | – | 200,000 | +100.0% | 0.12% | – |
| WMGIZ | New | WRIGHT MED GROUP N Vright 03/01/2019 | $10,558,000 | – | 6,900,000 | +100.0% | 0.12% | – |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $10,550,000 | +259.7% | 1,914,660 | +164.4% | 0.12% | +224.3% |
| INFI | INFINITY PHARMACEUTICALS INC | $10,498,000 | +139.2% | 3,250,300 | 0.0% | 0.12% | +112.5% | |
| FLDM | FLUIDIGM CORP DEL | $9,935,000 | -21.8% | 1,746,100 | 0.0% | 0.11% | -30.2% | |
| HRTX | New | HERON THERAPEUTICS INC | $9,750,000 | – | 650,000 | +100.0% | 0.11% | – |
| DMTX | DIMENSION THERAPEUTICS INC | $9,446,000 | -59.8% | 5,397,698 | 0.0% | 0.11% | -64.2% | |
| NUVA | NUVASIVE INC | $9,223,000 | +10.9% | 123,500 | 0.0% | 0.10% | -0.9% | |
| ALKS | New | ALKERMES PLC | $8,483,000 | – | 145,000 | +100.0% | 0.10% | – |
| CLLS | CELLECTIS S Asponsored ads | $8,400,000 | +41.6% | 350,000 | 0.0% | 0.10% | +25.0% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $8,103,000 | +7.5% | 372,191 | 0.0% | 0.09% | -4.2% | |
| IMMU | Sell | IMMUNOMEDICS INC | $7,972,000 | -42.9% | 1,232,100 | -67.6% | 0.09% | -49.4% |
| WMGI | New | WRIGHT MED GROUP N Vcall | $7,780,000 | – | 250,000 | +100.0% | 0.09% | – |
| NVRO | New | NEVRO CORP | $7,290,000 | – | 77,800 | +100.0% | 0.08% | – |
| TSRO | TESARO INC | $7,263,000 | +14.4% | 47,200 | 0.0% | 0.08% | +1.2% | |
| FLUIDIGM CORP DELnote 2.750% 2/0 | $6,815,000 | -2.8% | 10,000,000 | 0.0% | 0.08% | -13.5% | ||
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $6,651,000 | +22.5% | 484,800 | -36.0% | 0.08% | +8.7% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INCcall | $6,062,000 | -50.5% | 50,000 | -50.0% | 0.07% | -55.8% |
| ZBH | ZIMMER BIOMET HLDGS INC | $5,983,000 | +18.3% | 49,000 | 0.0% | 0.07% | +6.2% | |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $5,705,000 | -12.7% | 704,300 | +26.6% | 0.06% | -21.7% |
| SRRA | New | SIERRA ONCOLOGY INC | $5,667,000 | – | 3,703,704 | +100.0% | 0.06% | – |
| BMY | New | BRISTOL MYERS SQUIBB COcall | $5,438,000 | – | 100,000 | +100.0% | 0.06% | – |
| RDHL | REDHILL BIOPHARMA LTDsponsored ads | $5,417,000 | -8.3% | 564,900 | 0.0% | 0.06% | -18.7% | |
| NVTA | INVITAE CORP | $5,051,000 | +39.3% | 456,666 | 0.0% | 0.06% | +23.9% | |
| NLNK | New | NEWLINK GENETICS CORPcall | $4,820,000 | – | 200,000 | +100.0% | 0.06% | – |
| AFMD | Sell | AFFIMED N V | $4,643,000 | -23.6% | 2,018,900 | -40.2% | 0.05% | -31.2% |
| INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $4,433,000 | -39.7% | 7,000,000 | 0.0% | 0.05% | -46.8% | ||
| SIEN | Sell | SIENTRA INC | $4,397,000 | -30.5% | 522,257 | -29.7% | 0.05% | -38.3% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $4,213,000 | – | 82,200 | +100.0% | 0.05% | – |
| ROKA | ROKA BIOSCIENCE INC | $3,181,000 | -16.0% | 893,470 | 0.0% | 0.04% | -25.0% | |
| New | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $2,591,000 | – | 5,210,000 | +100.0% | 0.03% | – | |
| XENE | Sell | XENON PHARMACEUTICALS INC | $2,539,000 | -67.0% | 634,812 | -36.5% | 0.03% | -70.4% |
| CLSD | CLEARSIDE BIOMEDICAL INC | $2,382,000 | -11.2% | 300,000 | 0.0% | 0.03% | -20.6% | |
| VRX | VALEANT PHARMACEUTICALS INTL | $2,150,000 | -24.0% | 194,900 | 0.0% | 0.02% | -33.3% | |
| AMRN | AMARIN CORP PLCspons adr new | $1,120,000 | +3.9% | 350,000 | 0.0% | 0.01% | -7.1% | |
| NVLNF | NOVELION THERAPEUTICS INC | $1,074,000 | +27.6% | 100,000 | 0.0% | 0.01% | +9.1% | |
| BLRX | BIOLINERX LTDsponsored adr | $998,000 | +4.4% | 1,038,600 | 0.0% | 0.01% | -8.3% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $1,005,000 | +75.4% | 567,600 | 0.0% | 0.01% | +57.1% | |
| VNDA | New | VANDA PHARMACEUTICALS INC | $703,000 | – | 50,200 | +100.0% | 0.01% | – |
| BIOMARIN PHARMACEUTICAL INCnote 1.500%10/1 | $593,000 | +0.7% | 500,000 | 0.0% | 0.01% | -12.5% | ||
| BIOMARIN PHARMACEUTICAL INCnote 0.750%10/1 | $567,000 | +0.9% | 500,000 | 0.0% | 0.01% | -14.3% | ||
| ALIM | ALIMERA SCIENCES INC | $350,000 | +29.6% | 250,000 | 0.0% | 0.00% | +33.3% | |
| XTNT | XTANT MED HLDGS INC | $296,000 | +13.4% | 475,439 | 0.0% | 0.00% | 0.0% | |
| MDGS | New | MEDIGUS LTDsponsord adr new | $185,000 | – | 60,000 | +100.0% | 0.00% | – |
| ARLZ | Exit | ARALEZ PHARMACEUTICALS INC | $0 | – | -68,143 | -100.0% | -0.00% | – |
| MDGS | Exit | MEDIGUS LTDsponsored adr | $0 | – | -600,000 | -100.0% | -0.00% | – |
| Exit | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $0 | – | -5,210,000 | -100.0% | -0.02% | – | |
| SGMO | Exit | SANGAMO BIOSCIENCES INC | $0 | – | -707,400 | -100.0% | -0.03% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -204,400 | -100.0% | -0.03% | – |
| AMED | Exit | AMEDISYS INC | $0 | – | -71,500 | -100.0% | -0.04% | – |
| Exit | INCYTE CORPnote 0.375%11/1 | $0 | – | -4,250,000 | -100.0% | -0.11% | – | |
| Exit | INCYTE CORPnote 1.250%11/1 | $0 | – | -4,250,000 | -100.0% | -0.11% | – | |
| ABT | Exit | ABBOTT LABS | $0 | – | -245,400 | -100.0% | -0.12% | – |
| LLY | Exit | LILLY ELI & COcall | $0 | – | -150,000 | -100.0% | -0.14% | – |
| ITEK | Exit | INOTEK PHARMACEUTICALS CORP | $0 | – | -1,849,300 | -100.0% | -0.14% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INCcall | $0 | – | -750,000 | -100.0% | -0.15% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -169,300 | -100.0% | -0.15% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -798,000 | -100.0% | -0.15% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -551,500 | -100.0% | -0.16% | – |
| HUM | Exit | HUMANA INCcall | $0 | – | -100,000 | -100.0% | -0.26% | – |
| MOH | Exit | MOLINA HEALTHCARE INC | $0 | – | -496,200 | -100.0% | -0.34% | – |
| AGNPRA | Exit | ALLERGAN PLCpfd conv ser a | $0 | – | -88,200 | -100.0% | -0.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
About Orbimed Advisors
Orbimed Advisors is a leading healthcare-focused investment firm that manages over $16 billion in assets. The firm was founded in 1998 by Samuel Isaly, who has over 50 years of experience in the healthcare industry. Isaly is widely regarded as a pioneer in the field of healthcare investing and has been recognized for his contributions to the industry by numerous organizations.
Orbimed Advisors has a team of over 100 professionals, including investment professionals, research analysts, and operational experts. The firm has offices in New York, San Francisco, Shanghai, and Mumbai, and invests in companies across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
The firm's investment philosophy is based on a deep understanding of the healthcare industry and a rigorous approach to due diligence. Orbimed Advisors seeks to identify companies with innovative technologies and strong management teams that have the potential to transform the healthcare landscape.
Orbimed Advisors has a strong track record of success, with numerous successful investments in companies such as Juno Therapeutics, Spark Therapeutics, and Kite Pharma. The firm's leadership team, which includes CEO Sven Borho, COO Jonathan Silverstein, and Chief Investment Officer Carl Gordon, has decades of experience in the healthcare industry and is widely respected for their expertise and insights.
Overall, Orbimed Advisors is a leading healthcare investment firm that has a proven track record of success and a deep understanding of the healthcare industry. Investors looking to gain exposure to the healthcare sector may want to consider Orbimed Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 42 | Q3 2023 | 5.0% |
| VERTEX PHARMACEUTICALS INC | 42 | Q3 2023 | 3.7% |
| THERMO FISHER SCIENTIFIC INC | 42 | Q3 2023 | 3.2% |
| SINOVAC BIOTECH LTD | 41 | Q3 2023 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 41 | Q3 2023 | 2.7% |
| BOSTON SCIENTIFIC CORP | 40 | Q3 2023 | 5.6% |
| BRISTOL-MYERS SQUIBB CO | 40 | Q2 2023 | 5.2% |
| AMGEN INC | 40 | Q3 2023 | 5.5% |
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.8% |
| GILEAD SCIENCES INC | 39 | Q3 2023 | 5.5% |
View Orbimed Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ikena Oncology, Inc. | September 21, 2023 | 2,189,111 | 5.2% |
| Galecto, Inc. | September 18, 2023 | 749,557 | 2.8% |
| PMV Pharmaceuticals, Inc. | August 23, 2023 | 6,563,077 | 13.5% |
| Gracell Biotechnologies Inc. | August 11, 2023 | 7,641,531 | 8.0% |
| Xtant Medical Holdings, Inc. | August 03, 2023 | 73,114,592 | 56.7% |
| Turnstone Biologics Corp. | July 24, 2023 | 3,099,265 | 13.4% |
| Prelude Therapeutics Inc | May 24, 2023 | 15,716,642 | 28.6% |
| VectivBio Holding AG | May 24, 2023 | 5,156,561 | 7.7% |
| Fusion Pharmaceuticals Inc. | May 16, 2023 | 2,930,670 | 4.6% |
| Verona Pharma plc | May 16, 2023 | 3,777,778 | 4.8% |
View Orbimed Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-26 |
| 4 | 2024-04-23 |
| 4 | 2024-04-18 |
| 4 | 2024-04-15 |
| 3/A | 2024-04-12 |
| SC 13D/A | 2024-04-12 |
| 4 | 2024-04-05 |
| SC 13D/A | 2024-04-04 |
| 3 | 2024-04-03 |
| SC 13D | 2024-03-28 |
View Orbimed Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.